Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi133-vi135; doi:10.1093/annonc/mdm242
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Orditura, M
Right arrow Articles by De Vita, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orditura, M
Right arrow Articles by De Vita, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

gastro-intestinal cancer

Chemoradiotherapy as adjuvant treatment of gastric cancer

M Orditura1,*, E Martinelli1, G Galizia2, F Vitiello1, M Fasano1, P Muto3, F Ciardiello1 and F De Vita1

1 Department of Medical Oncology
2 Department of Surgical Oncology, F. Magrassi & A. Lanzara, Second University of Naples School of Medicine, Naples
3 Division of Radiation Therapy ‘Ascalesi’ Hospital, Naples, Italy

* Correspondence to: M. Orditura, Department F. Magrassi & A. Lanzara, Second University of Naples School of Medicine, II Policlinico, via S. Pansini, 5, 80131 Naples, Italy. Tel/Fax: +39-081642948; E-mail: michele.orditura{at}unina2.it

Historically, radiotherapy has been occasionally used in the treatment of gastric cancer. More recently, the results of INT-0116 trial have shown an improvement of disease-free and overall survival by chemoradiation with a significant impact on the management of this tumor. Based on these data, there has been an increasing interest in radiotherapy and its association with chemotherapy for patients with locoregional disease as a part of an adjuvant treatment after surgery in high-risk patients. However, many questions remain to evaluate; first of all the toxicity of this approach and its efficacy after adequate surgery.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.